JP2023542124A5 - - Google Patents

Info

Publication number
JP2023542124A5
JP2023542124A5 JP2023517243A JP2023517243A JP2023542124A5 JP 2023542124 A5 JP2023542124 A5 JP 2023542124A5 JP 2023517243 A JP2023517243 A JP 2023517243A JP 2023517243 A JP2023517243 A JP 2023517243A JP 2023542124 A5 JP2023542124 A5 JP 2023542124A5
Authority
JP
Japan
Prior art keywords
gprc5d
bispecific antibody
seq
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075523 external-priority patent/WO2022058445A1/en
Publication of JP2023542124A publication Critical patent/JP2023542124A/ja
Publication of JP2023542124A5 publication Critical patent/JP2023542124A5/ja
Pending legal-status Critical Current

Links

JP2023517243A 2020-09-16 2021-09-16 多発性骨髄腫を治療するための方法 Pending JP2023542124A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063079294P 2020-09-16 2020-09-16
US63/079,294 2020-09-16
US202063116549P 2020-11-20 2020-11-20
US63/116,549 2020-11-20
US202163187888P 2021-05-12 2021-05-12
US63/187,888 2021-05-12
PCT/EP2021/075523 WO2022058445A1 (en) 2020-09-16 2021-09-16 Methods for treating multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023542124A JP2023542124A (ja) 2023-10-05
JP2023542124A5 true JP2023542124A5 (cg-RX-API-DMAC7.html) 2024-09-25

Family

ID=77924410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517243A Pending JP2023542124A (ja) 2020-09-16 2021-09-16 多発性骨髄腫を治療するための方法

Country Status (11)

Country Link
US (1) US20220177584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213945A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542124A (cg-RX-API-DMAC7.html)
KR (1) KR20230069959A (cg-RX-API-DMAC7.html)
CN (1) CN116322769A (cg-RX-API-DMAC7.html)
AU (1) AU2021346129A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3194796A1 (cg-RX-API-DMAC7.html)
IL (1) IL301361A (cg-RX-API-DMAC7.html)
MX (1) MX2023003086A (cg-RX-API-DMAC7.html)
WO (1) WO2022058445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP4585615A4 (en) 2022-09-09 2026-07-08 Beijing Mabworks Biotech Co Ltd Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
TW202448927A (zh) * 2023-02-28 2024-12-16 美商健生生物科技公司 包含雙特異性gprc5d/cd3抗體之組成物
EP4698217A1 (en) * 2023-04-19 2026-02-25 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2024370419A1 (en) 2023-10-31 2026-06-11 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体

Similar Documents

Publication Publication Date Title
JP2021526136A5 (cg-RX-API-DMAC7.html)
JP2024540054A5 (cg-RX-API-DMAC7.html)
JP2018520101A5 (cg-RX-API-DMAC7.html)
IL278667B1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
JP2017528462A5 (cg-RX-API-DMAC7.html)
JP2021519295A5 (cg-RX-API-DMAC7.html)
TWI890481B (zh) 雙特異性抗體
JP2015500822A5 (cg-RX-API-DMAC7.html)
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2021528423A5 (cg-RX-API-DMAC7.html)
CA2984464C (en) Treatment for multiple myeloma (mm)
WO2019186273A4 (en) Subcutaneous dosing of anti-cd38 antibodies
JP2021512107A5 (cg-RX-API-DMAC7.html)
JP2011507932A5 (cg-RX-API-DMAC7.html)
JP2023505218A5 (cg-RX-API-DMAC7.html)
HRP20191115T1 (hr) Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
JP2017507953A5 (cg-RX-API-DMAC7.html)
EP2192921A1 (de) Intraoperative trifunktionale antikörper-applikation zur prophylaxe intraperitonealer tumorzelldissemination
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2024516698A5 (cg-RX-API-DMAC7.html)
JP2021528438A5 (cg-RX-API-DMAC7.html)
JP2024509332A5 (cg-RX-API-DMAC7.html)
JP2023542291A5 (cg-RX-API-DMAC7.html)
RU2020112490A (ru) Антитела из тяжелых цепей, связывающиеся с эктоферментами
EP4288100A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells